Ryan Preblick
Chief Financial Officer at Indivior Pharmaceuticals, Inc. (INDV) since January 2026
Ryan Preblick has filed 5 insider reports with the SEC since January 2026, as chief Financial Officer at Indivior Pharmaceuticals, Inc. (INDV). In the last 12 months Ryan Preblick sold $1.36M of stock on the open market. In the latest filing, on June 10, 2026, Ryan Preblick sold 36,000 shares of Indivior Pharmaceuticals, Inc. (INDV) for $1.36M at an average of $37.70.
- Filings
- 5
- Companies
- 1
- Bought on market
- None
- Sold on market
- $1.36M
Companies where Ryan Preblick is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Financial Officersince January 2026 | 284,751 | $1.36M | $36.28 | Jun 10, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 8, 2026-$1.36MINDVChief Financial Officer Preblick Ryan sold $1,357,200 worth of shares (36,000 units at $37.70) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 284,751 unitsForm 4Open-market sale10b5-1 plan
- Mar 14, 2026INDVChief Financial Officer Preblick Ryan converted options into 6,302 shares and covered exercise/tax liability with 2,843 shares, increasing direct ownership by 1% to 320,751 unitsForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Mar 3, 2026INDVChief Financial Officer Preblick Ryan covered exercise/tax liability with 87,597 shares and converted options into 86,949 shares, decreasing direct ownership by 0.20% to 317,292 unitsForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Feb 10, 2026INDVChief Financial Officer Preblick Ryan was granted 37,358 shares, increasing direct ownership by 13% to 317,940 unitsForm 4Grant or award
- Jan 1, 2026INDVNew insider Preblick Ryan claimed ownership of 280,582 units of Ordinary SharesForm 3New insider
Compare Ryan Preblick with
- Ryan Preblick vs Frank Mottola1 shared
- Ryan Preblick vs William Todd Horich1 shared
- Ryan Preblick vs Timothy C Dec1 shared
- Ryan Preblick vs Carrolee Barlow1 shared
- Ryan Preblick vs Padmanabh P. Bhatt1 shared
- Ryan Preblick vs Bethany Sensenig1 shared
Other insiders at the same companies
- Frank MottolaINDV
- William Todd HorichINDV
- Timothy C DecINDV
- Carrolee BarlowINDV
- Padmanabh P. BhattINDV
- Bethany SensenigINDV
- Georges GemayelINDV
- Jack A. KhattarINDV
- Jonathan RubinINDV
- Woodrow D AndersonINDV
- Christian HeidbrederINDV
- Joseph CiaffoniINDV
- Juliet ThompsonINDV
- Keith HumphreysINDV
- Stuart A KingsleyINDV
- Daniel A NinivaggiINDV
Questions about Ryan Preblick
- What is Ryan Preblick's role at Indivior Pharmaceuticals, Inc.?
- Ryan Preblick reports to the SEC as chief Financial Officer at Indivior Pharmaceuticals, Inc. (INDV), according to the latest filing on June 10, 2026.
- How many shares does Ryan Preblick own?
- After the latest filing that states it, Ryan Preblick directly owned 284,751 shares of Indivior Pharmaceuticals, Inc. (INDV). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Ryan Preblick bought or sold stock recently?
- The most recent open-market sale was on June 8, 2026: sold 36,000 shares of Indivior Pharmaceuticals, Inc. (INDV) for $1.36M at an average of $37.70.
- How do I get alerts when Ryan Preblick files?
- Follow Ryan Preblick on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Ryan Preblick (SEC CIK 0002014866). Totals count each trade once, skipping amendments whose original is on file, from Jan 7, 2026 on. View on SEC EDGAR